These considerations will enable a more nuanced assessment of the impact of tumor heterogeneity characterized by TAM component and TGFB2/IFN-I activation mechanisms to predict clinical outcomes and to provide biomarkers for stratified analyses based on molecular characteristics of PDAC tumors. The gene discussed is TGFB2; the disease is neoplasm.